Bullish
GRFS or NBIX: Which Is the Better Value Stock Right Now?
GRFS vs. NBIX: Which Stock Is the Better Value Option?
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
52W High
$154.61
52W Low
$84.23
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.28
Valuation
Rich
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
42.51
Forward P/E (<15 better)
27.25
EV/EBITDA (<8 favorable)
24.69
EV/Revenue (<3 favorable)
5.48
P/S (TTM) (<3 favorable)
5.69
P/B (<3 favorable)
5.30
Ownership
Institution‑heavySource: Overview
Insiders (1–5% typical)
1.05%
Institutions (25–75% balanced)
102.05%
Shares Outstanding
99,182,000
Float
98,003,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
1995-12-29
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
2,509,900,000
Gross Profit (TTM)
1,584,000,000
EPS (TTM)
3.39
Profit Margin (>10% good)
0.14%
Operating Margin (TTM) (higher better)
0.21%
ROE (TTM) (>15% strong)
0.13%
EPS YoY (Quarterly) (>10% good)
0.68
Revenue YoY (Quarterly) (>8% good)
0.17
Momentum
Bearish momentumValue
3.6350
Previous
3.8437
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025